# TDM-based Infliximab Treatment for Active Perianal Fistulizing Crohn's Disease

> **NCT06051253** · PHASE4 · RECRUITING · sponsor: **Asan Medical Center** · enrollment: 86 (estimated)

## Conditions studied

- Crohn Disease
- Infliximab
- Perianal Fistula Due to Crohn's Disease
- Therapeutic Drug Monitoring
- Magnetic Resonance Novel Index for Fistula Imaging in Crohn's Disease Score

## Interventions

- **DRUG:** TDM-based infliximab intravenous therapy
- **DRUG:** Standard infliximab intravenous therapy

## Key facts

- **NCT ID:** NCT06051253
- **Lead sponsor:** Asan Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-11-01
- **Primary completion:** 2026-06-30
- **Final completion:** 2027-06-30
- **Target enrollment:** 86 (ESTIMATED)
- **Last updated:** 2024-05-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06051253

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06051253, "TDM-based Infliximab Treatment for Active Perianal Fistulizing Crohn's Disease". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT06051253. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*